Barrons.com8d agobearish
Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.